Back to top

Analyst Blog

Zacks Equity Research

ViroPharma's Seizure Drug Reaches UK

HALO

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

ViroPharma Inc. recently announced the launch of its epilepsy drug, Buccolam, in the United Kingdom (UK). The drug is approved for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, aged 3 months to 18 years.

We note that the European Commission granted Buccolam a Centralized Pediatric Use Marketing Authorization (PUMA) for the said indication in September 2011. PUMA is a new type of centralized marketing authorization procedure for medicines that are already authorized, but are no longer covered by intellectual property rights. Also, the PUMA-authorized drugs are exclusively developed for children.

Buccolam became a part of ViroPharma’s portfolio following the acquisition of Auralis Limited in May 2010.

The UK launch of Buccolam for convulsive seizures is an important milestone for ViroPharma after the European approval of Buccolam and the approval of Cinryze for the treatment of hereditary angioedema (HAE) in mid-June 2011.

Cinryze is indicated for the treatment of pre-procedure prevention of angioedema attacks in adults and adolescents with HAE, and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of HAE, who are intolerant of or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.

We note that in May 2011, ViroPharma entered into a global licensing deal with Halozyme Therapeutics, Inc. (HALO - Snapshot Report), for using the latter’s rHuPH20 (recombinant human hyaluronidase) for the development of a subcutaneous formulation of Cinryze, which is currently in phase II. The agreement requires ViroPharma to fund all the development and commercialization expenses related to the program.

We currently have a Neutral recommendation on ViroPharma. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%